FTI 276 TFA is primarily used in research settings to study cellular processes and signaling pathways. It acts as a selective inhibitor of farnesyltransferase, an enzyme involved in the post-translational modification of proteins. By inhibiting this enzyme, it helps researchers understand the role of protein farnesylation in cell growth, differentiation, and cancer development. It is particularly valuable in studying Ras protein signaling, which is often implicated in various cancers. Additionally, it is used to explore potential therapeutic strategies for diseases where farnesyltransferase activity is dysregulated, such as certain types of tumors and progeria. Its application extends to preclinical studies aimed at developing targeted cancer therapies.